Groowe Groowe / Newsroom / SABS
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

SABS News

SAB Biotherapeutics, Inc. Common Stock

SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress

globenewswire.com
SABS SABSW

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

globenewswire.com
SABS

Form 8-K

sec.gov
SABS SABSW

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

globenewswire.com
SABS

SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

globenewswire.com
SABS SABSW

Form 8-K

sec.gov
SABSW SABS

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

globenewswire.com
SABS SABSW

SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

globenewswire.com
SABS

SAB BIO to Participate in Upcoming Investor Conferences

globenewswire.com
SABS SABSW

SAB BIO to Participate in Upcoming Investor Conferences

globenewswire.com
SABS SABSW